Significance of treatment response when managing patients with primary central nervous system lymphoma.
Leuk Lymphoma. 2018 Jul 03;:1-9
Zinc Finger Protein 521 regulates early hematopoiesis through cell extrinsic mechanisms in the bone marrow microenvironment.
Mol Cell Biol. 2018 Jun 18;:
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
Bone Marrow Transplant. 2018 Jun 12;:
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
J Clin Oncol. 2018 Mar 27;:JCO2017760793
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
J Clin Oncol. 2018 Feb 02;:JCO2017773994
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review.
BMJ Open. 2018 Jan 27;8(1):e017578
Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
Bone Marrow Transplant. 2017 Dec 21;:
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
Ann Oncol. 2017 Dec 15;:
Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML.
Eur J Haematol. 2017 Nov 23;: